Browse through all publications from the Institute of Global Health Innovation, which our Patient Safety Research Collaboration is part of. This feed includes reports and research papers from our Centre. 

Citation

BibTex format

@article{Moshe:2021,
author = {Moshe, M and Daunt, A and Flower, B and Simmons, B and Brown, JC and Frise, R and Penn, R and Kugathasan, R and Petersen, C and Stockmann, H and Ashby, D and Riley, S and Atchison, C and Taylor, GP and Satkunarajah, S and Naar, L and Klaber, R and Badhan, A and Rosadas, C and Marchesin, F and Fernandez, N and Sureda-Vives, M and Cheeseman, H and O'Hara, J and Shattock, R and Fontana, G and Pallett, SJC and Rayment, M and Jones, R and Moore, LSP and Ashrafian, H and Cherapanov, P and Tedder, R and McClure, M and Ward, H and Darzi, A and Cooke, GS and Barclay, WS and On, behalf of the REACT Study team},
journal = {BMJ: British Medical Journal},
pages = {1--8},
title = {SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (REACT2): diagnostic accuracy study},
url = {https://www.bmj.com/content/372/bmj.n423},
volume = {372},
year = {2021}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Objective: To evaluate the performance of new lateral flow immunoassays (LFIAs) suitable for use in a national COVID-19 seroprevalence programme (REACT2).Design: Laboratory sensitivity and specificity analyses were performed for seven LFIAs on a minimum of 200 sera from individuals with confirmed SARS-CoV-2 infection, and 500 pre-pandemic sera respectively. Three LFIAs were found to have a laboratory sensitivity superior to the finger-prick sensitivity of the LFIA currently used in REACT2 seroprevalence studies (84%). These LFIAs were then further evaluated through finger-prick testing on participants with confirmed previous SARS-CoV-2 infection. Two LFIAs (Surescreen, Panbio) were evaluated in clinics in June-July, 2020, and a third LFIA (AbC-19) in September, 2020. A Spike protein enzyme-linked immunoassay (S-ELISA) and hybrid double antigen binding assay (DABA) were used as laboratory reference standards.Setting: Laboratory analyses were performed at Imperial College, London and University facilities in London, UK. Research clinics for finger-prick sampling were run in two affiliated NHS trusts.Participants: Sensitivity analysis on sera were performed on 320 stored samples from previous participants in the REACT2 programme with confirmed previous SARS-CoV-2 infection. Specificity analysis was performed using 1000 pre-pandemic sera. 100 new participants with confirmed previous SARS-CoV-2 infection attended study clinics for finger-prick testing.Main outcome measures: The accuracy of LFIAs in detecting IgG antibodies to SARS-CoV-2 in comparison to two in-house ELISAs.Results: The sensitivity of seven new LFIAs using sera varied between 69% and 100% (vs S-ELISA/hybrid DABA). Specificity using sera varied between 99.6% and 100%. Sensitivity on finger-prick testing for Panbio, Surescreen and AbC-19 was 77% (CI 61.4 to 88.2), 86% (CI 72.7 to 94.8) and 69% (CI 53.8 to 81.3) respectively vs S-ELISA/hybrid DABA. Sensitivity for sera from matched clinical samples performe
AU - Moshe,M
AU - Daunt,A
AU - Flower,B
AU - Simmons,B
AU - Brown,JC
AU - Frise,R
AU - Penn,R
AU - Kugathasan,R
AU - Petersen,C
AU - Stockmann,H
AU - Ashby,D
AU - Riley,S
AU - Atchison,C
AU - Taylor,GP
AU - Satkunarajah,S
AU - Naar,L
AU - Klaber,R
AU - Badhan,A
AU - Rosadas,C
AU - Marchesin,F
AU - Fernandez,N
AU - Sureda-Vives,M
AU - Cheeseman,H
AU - O'Hara,J
AU - Shattock,R
AU - Fontana,G
AU - Pallett,SJC
AU - Rayment,M
AU - Jones,R
AU - Moore,LSP
AU - Ashrafian,H
AU - Cherapanov,P
AU - Tedder,R
AU - McClure,M
AU - Ward,H
AU - Darzi,A
AU - Cooke,GS
AU - Barclay,WS
AU - On,behalf of the REACT Study team
EP - 8
PY - 2021///
SN - 0959-535X
SP - 1
TI - SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (REACT2): diagnostic accuracy study
T2 - BMJ: British Medical Journal
UR - https://www.bmj.com/content/372/bmj.n423
UR - http://hdl.handle.net/10044/1/86108
VL - 372
ER -

NIHR logo